COLON IRRITABILE. UNA REVIEW DA CAMILLERI

Diagnosis and Treatment of Irritable Bowel Syndrome. A Review Michael Camilleri, MD Abstract Importance  The prevalence of irritable bowel syndrome (IBS) in the United States is between 7% and 16%, most common in women and young people, with annual direct costs estimated at more than $1 billion dollars in the United States. Traditionally, the diagnosis of…

UNO SCORE DI FACILE USO PER IDENTIFICARE IL PAZIENTE CON CIRROSI NEL TUO STUDIO

Can routine blood tests be modelled to detect advanced liver disease in the community: model derivation and validation using UK primary and secondary care data  Theresa Hydes et al. Abstract Objectives Most patients are unaware they have liver cirrhosis until they present with a decompensating event. We therefore aimed to develop and validate an algorithm to…

UN CALCOLATORE MOLTO ACCURATO PER LA PROGNOSI DEL PAZIENTE CON COVID-19

Development of Severe COVID-19 Adaptive Risk Predictor (SCARP), a Calculator to Predict Severe Disease or Death in Hospitalized Patients With COVID-19 FREE Shannon Wongvibulsin et al. Abstract Background: Predicting the clinical trajectory of individual patients hospitalized with coronavirus disease 2019 (COVID-19) is challenging but necessary to inform clinical care. The majority of COVID-19 prognostic tools…

Più di 140,000 differenti virus vivono nell’intestino umano.

Massive expansion of human gut bacteriophage diversity Luis F. Camarillo-Guerrer et al. Highlights • Database containing 142,809 non-redundant gut phage genomes from 28,060 metagenomes • Host assignment reveals phage diversity and host range across gut bacteria isolates • Epidemiology analysis unveils 280 viral clusters that are globally distributed • The Gubaphage is a clade that…

REPLICAZIONE DEGLI STUDI CONTROLLATI NELLA “REAL WORLD EVIDENCE”: UN OTTIMO EDITORIALE

Replication of Randomized, Controlled Trials Using Real-World Data: What Could Go Wrong? David Thompson1 Abstract With the growing interest in using real-world evidence (RWE) for regulatory purposes, researchers and policy makers are considering how best to assess the credibility of RWE. Because the randomized controlled trial (RCT) has long been regarded as the gold standard…

TRIAL VERSUS “REAL WORLD EVIDENCE”: THE DUPLICATE INITIATIVE. UN PRIMO CONFRONTO SU STUDI IN CARDIOLOGIA E DIABETOLOGIA

Emulating Randomized Clinical Trials With Nonrandomized Real-World Evidence Studies: First Results From the RCT DUPLICATE Initiative Jessica M Franklin et al. Abstract Background: Regulators are evaluating the use of noninterventional real-world evidence (RWE) studies to assess the effectiveness of medical products. The RCT DUPLICATE initiative (Randomized, Controlled Trials Duplicated Using Prospective Longitudinal Insurance Claims: Applying Techniques…